Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDC*lung01 in NSCLC with or without anti-PD-1 therapy
NL-OMON56303Phase 2Recruiting
- Sponsor
- PDC*line Pharma
- Start
- Nov 2021
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of PDC*lung01 in non-small cell lung cancer (NSCLC) (5 cohorts), sponsored by PDC*line Pharma. Primary endpoint: Dose-limiting toxicities. Started Nov 2021; status: recruiting.
02
Drugs
PDC*lung01
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON56303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56303.